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Primary sclerosing cholangitis is a rare cause of cholestasis caused by progressive inﬂammation and ﬁbrosis of both intrahepatic
and extrahepatic bile ducts leading to multifocal ductal strictures. Herein, we report a case of primary sclerosing cholangitis
and inﬂammatory bowel disease. The concomitant diagnosis of these two diseases is not typical. The management includes
the treatment of inﬂammatory bowel disease and potential complications of primary sclerosing cholangitis, including dominant
strictures of bile duct, portal hypertension, gallbladder diseases, cholangiocarcinoma, and colonoscopic surveillance.
1.Introduction
Primary sclerosing cholangitis is a rare cause of chronic
cholestasis in adult with prevalence of about 1–5/100,000
in Caucasian inhabitants. There is a close association with
inﬂammatory bowel disease. The clinical course is, yet vari-
able and unpredictable, slowly progressive and develops into
biliary cirrhosis and corresponding complications. Thera-
peutic measures aim in improving bile ﬂow to prevent the
progression of biliary obstruction and liver transplantation
is the treatment of choice in advanced stage of the disease.
2.CaseReport
A 31-year-old man was admitted to the hospital because of
hypochromic microcytic anemia
He had chronic nonspeciﬁc epigastric pain for the past
six months which had bloating sensation without radiation
and any relationship to meal. He consulted a private
practitioner. The complete blood picture showed that the
hemoglobin was only 6g/dl, and so he was referred to our
unit for further management. His appetite reduced with
subjective weight loss in the past three months’time. His
bowel opening increased up to two times per day more loose
in nature. All being along there was no per rectal bleeding.
His past health was well except for taking herbal medicine
for acne for the past seven months.
On examination he was pale with the absence of stigmata
of chronic liver disease. The abdominal examination showed
hepatomegaly. Laboratory data were as follows: hemoglobin,
4.3g/dL (normal: 13.4–17.2); mean cell volume, 49.6ﬂ
(normal: 83–98); white blood cell count, 9/mm3 (normal:
3.9–10.7); platelet count, 508/mm3 (normal: 152–358);
total bilirubin, 17umol/L (normal: 5–20); alkaline phos-
phatase, 1541IU/L (normal: 46–127); γ-glutamyl transpep-
tidase, 366IU/L (normal: 12–57); alanine aminotransferase,
102IU/L (normal: 10–57); albumin, 34g/l (normal: 35–50);
globulin, 40g/l (no reference); iron saturation, 1% (normal:
20–55); hemoglobin A2, 4.8% (normal: 1.6–3.5).
The preliminary investigations revealed that he had
severe iron deﬁciency anemia coexisting with β thalassaemia
trait and cholestatic liver derangement. The esophagogas-
troduodenoscopy (OGD) showed no abnormality down to
the third part of duodenum. Early colonoscopy performed
one week later showed that the colonic mucosa was ery-
thematous with loss of vascular pattern and multiple small
superﬁcial ulcerations in which the proximal parts including
ascending and transverse colon were more severely aﬀected.
The mucosa of terminal ileum, sigmoid, and rectum was
endoscopically normal looking. The histology revealed that
there was inﬂammatory cell inﬁltration at lamina propria
of terminal ileum, and colon, the latter also having dis-
torted cryptal architecture. The abdominal ultrasonography
showed that the liver was enlarged with 16.7cm of span2 Case Reports in Medicine
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Figure 1: ERCP showing irregular wall contours, variable intrahep-
atic stenoses, and two distal common bile duct stones.
Figure 2: Marked expansion of portal tracts by ﬁbrosis and inﬂam-
mation (low-power view).
length and dilated intrahepatic and common bile duct.
Further, relevant blood tests showed that the perinuclear
antineutrophil cytoplasmic antibodies (p-ANCAs) were
present while other autoimmune antibody (including antin-
uclear, antimitochondrial, antismooth muscle antibody),
HBsAg, anti-HCV and HIV antibody were absent.
During the next 3 days, his hemoglobin was topped up to
8.7g/dL by two units of packed cell. Then endoscopic ret-
rograde cholangiopancreatography (ERCP) was performed
and found multiple irregularities over bilateral intrahepatic
bile ducts: common bile duct was not dilated but with two
small stones distally (Figure 1) .T h e s es t o n e sw e r ee x t r a c t e d
after papillotomy. The liver biopsy was also performed and
revealed that the portal tracts had mixed inﬂammatory
inﬁltrate, some interlobular bile ducts having concentric,
laminated (onion-skin) ﬁbrosis around them, and focal bile
ductular proliferation. These were consistent with primary
sclerosingcholangitis,StageIII(Ludwig)(Figures2,3and4).
Therefore,thisgentlemanwasdiagnosedtohaveprimary
sclerosing cholangitis coexisting with ulcerative colitis. He
was put on medications including ursodeoxycholic acid
Figure 3: Concentric ﬁbrosis and portal tract inﬂammation (inter-
mediatepower view).
Figure 4: Atrophic interlobular bile duct (high-power view).
500mg bd, enteric coated mesalazine 2000mg bd, and
iron supplement. He was regularly followed up for the
past 4 months and his condition was stable in which his
hemoglobin remained static with hemoglobulin level around
9g/dl and the alkaline phosphatase improved to 204U/L.
3. Discussion
The diagnosis of primary sclerosing cholangitis (PSC) in this
patient is established by the biochemical proﬁle of chronic
cholestasis, typical strictures and pruning of the biliary tree
upon cholangiography, and ring ﬁbrosis around the bile
ducts in liver biopsy. The coexisting iron deﬁciency anemia
should lead to the suspiciousness of coexisting inﬂammatory
bowel disease which was conﬁrmed by colonoscopy in our
case.
Firstly reported by Dr. K. Delbet in 1924 by constellation
of symptoms including pruritus and cholestatic liver pattern,
PSC is characterized pathologically by the progressive,
ﬁbrous-stenosingandobliterating,predominantlysegmental
inﬂammation of the intra- and extrahepatic bile ducts andCase Reports in Medicine 3
preferably aﬀects male with a maximum age of around 25–
45 [1]. About 80% of patients show both intrahepatic and
extrahepatic involvement; 20% showed only extrahepatic
involvement [2].
Itislikelyanimmune-mediateddiseasewithawiderange
of autoantibodies detected in which p-ANCA, having the
highestprevalenceanddetectedinourpatient,occursin80%
of patients. Although it does not correlate with the activity of
PSC, it may draw attention to colon involvement [3].
For diagnostic imaging, the typical ﬁndings of ERCP
and MRCP in PSC are pearl-string-like changes of the bile
ducts with intermittent, diﬀusely distributed, multiple, and
irregular strictures of diﬀerent length. Nowadays MRCP
replaces the role of ERCP in the diagnosis of PSC because
it is noninvasive with high sensitivity and speciﬁcity (both
are greater than 80%) whereas ERCP can lead to potential
serious complications such as pancreatitis and bacterial
cholangitis [4]. As MRCP is not easily available in our centre,
ERCP was performed instead, and the typical strictures and
pruning ofthebiliarytreeweredemonstratedandtwostones
were found concurrently and removed uncomplicatedly in
the same session. The liver biopsy of our case revealed the
typical features of PSC. In fact, a liver biopsy is not required
in the presence of typical cholangiographic features of PSC
unless a small duct PSC is suspected because the disease
localizes in intrahepatic ducts [5]. It was performed in our
case because he was young with quite advanced laboratory
parameters and had an elevated serum aminotransferase.
Thus an accurate staging of the disease and exclusion of
a PSC-autoimmune hepatitis (PSC-AIH) are warranted. A
clinical entity called autoimmune pancreatitis (AIP-SC),
characterized by a lymphoplasmacytic inﬁltrate around pan-
creaticductandelevatedserumIgG4,cancausestricturingin
intrahepaticandextrahepaticbileductsimilartothatpresent
in PSC. Distinguishing from PSC, both PSC-AIH and AIP-
SC are responsive to corticosteroid [6].
PSC is strongly associated with inﬂammatory bowel
disease (IBD) in which up to 80% are associated with
ulcerative colitis (UC), and only 10% Crohn’s disease with
the latter is usually diagnosed before PSC [7]. As IBD in PSC
may be asymptomatic, and therefore any newly diagnosed
PSC should have full colonoscopy with biopsies. Although
IBD may be diagnosed at any time during the course of PSC,
the concomitant presentation like in our case is not typical
[8]. There are several clinical and endoscopic features of IBD
in PSC distinctive from ordinary IBD in which the former
usually has more pancolitis, rectal sparing, and backwash
ileitis.Thesementionedfeaturesarepresentinourpatient.In
addition, IBD has more frequently quiescent and prolonged
subclinical course [9, 10]. The medical therapy does not
diﬀer from that of IBD without PSC. The indications for
urgent surgery are acute severe colitis not responding to
medical treatment, toxic dilatation, perforation, or hemor-
rhage while the indications for elective surgery fall into two
groups: failure of medical therapy and dysplastic/malignant
change in the colon. Proctocolectomy with ileal pouchanal
anastomosisisnowtheprocedureofchoicebecauseithasthe
advantage of both removing the diseased colon and avoiding
a permanent ileostomy. Patients with UC and PSC are at
higher risk of colorectal neoplasia compared with those with
UC alone, with odd ratio 4.79 and predilection for right-
side distribution [11]. Thus, surveillance colonoscopy with
biopsies at up to two-year intervals is recommended.
There is no eﬀective medical treatment of PSC; the
routine use of ursodeoxycholic acid (UDCA) is not rec-
ommended because of unclear beneﬁt and possible serious
adverse eﬀects in high dose (28–30mg/kg/day) [12]. Treat-
ment with corticosteroid and other immunosuppressant
agents does not show any beneﬁcial eﬀect. However, our case
received UDCA of the dose around 15mg/kg/day, and his
serum liver ductal enzymes seemed improving, but the long-
term eﬀect needs to be observed.
The management of our patient should also include
management of potential complications including portal
hypertension, dominant strictures of bile ducts, gallbladder
diseases, cholangiocarcinoma, and colorectal neoplasia.
Concerning portal hypertension, about 40% newly diag-
nosed cases have esophageal varices, and its management
does not diﬀer from non-PSC patients [13]. The dominant
strictureinPSCisdeﬁnedasastenosiswithadiameterofless
than1.5mmincommonbileductorof1mminintrahepatic
ducts [14]. It happens in about 50% of patients during
the followup, and the common presentations are jaundice,
pruritus, right-upper quadrant pain, and elevated serum
bilirubin. The management is to relieve biliary obstruction
by endoscopic balloon dilatation with or without stent
placement preceded by the brush cytology and biopsy at
the stricture site to exclude a superimposed malignancy
[15]. In an early case series, the gallbladder abnormalities
are frequently observed, including gallstones (26%), PSC
involving gallbladder (15%), and neoplasm of gallbladder
(4%) [16]. Therefore, an annual ultrasound of biliary system
is recommended to detect mass lesions in the gallbladder.
In our case, the coexisting common bile duct stones might
be formed in situ or migrated from the gallbladder. Lastly,
PSC is a risk factor for cholangiocarcinoma, with 10% ten-
year cumulative incidence [17]. It is a diﬃcult task to dis-
tinguish it from the benign stricture. Because of lack of any
diagnostic test, the diagnosis of cholangiocarcinoma relies
on the following features: contrast-enhanced mass lesion
in imaging, positive biopsy/cytology, or highly elevated CA
19-9 in case of borderline resulting from imaging and histol-
ogy.Forearlystageofcholangiocarcinoma,surgicalresection
is indicated in patient of good liver functional condition
while liver transplantation following neoadjuvant therapy is
an option in case of poor liver reserve [18].
The natural course of PSC depends on the respective
stage at the time of diagnosis, and its survival rate is around
60% after 6 years [19]. Because of the absence of eﬀective
treatment available, there are several prognostic models to
predict the clinical outcome, such as Mayo score, which
is shown to be useful in predicting the clinical course
particularly the early stage of PSC, and this score includes
age,bilirubin, serumaminotransferase,albumin,andhistory
of variceal bleeding [20]. Liver transplant indications for
patient with PSC include liver failure and several unique
indications such as intractable pruritus, recurrent bacterial
cholangitis, and cholangiocarcinoma. The appropriate time4 Case Reports in Medicine
for referral for liver transplantation includes one of the
following: Child-Pugh score of seven, model for end-stage
liver disease (MELD) of 10, or any complication of portal
hypertension. Overall, the results of liver transplantation are
good with 70% in 10-year survival rates [21, 22]. The risk of
developing colonic neoplasia in ulcerative colitis still persists
after transplantation, and therefore annual colonoscopic
surveillance is still warranted. In our patient, he has been
regularly followed up with stable condition, and he is
planned to have regular ultrasound imaging of hepatobiliary
system and colonoscopic surveillance.
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